高危t(8;21)急性髓系白血病患者的识别与复发防控

Identify and Prevent Relapse of High-risk Acute Myeloid Leukemia Patients with t(8;21)

急性髓系白血病(AML)伴t(8;21)是AML常见类型之一,多项研究表明t(8;21)AML是一组异质性疾病,因而早期识别高危患者进而调整治疗方案有助于提高治疗疗效,改善患者整体预后。根据治疗前合并基因突变、初治外周血白细胞计数、CD56表达及治疗后微小残留病水平可将患者预后再分层。基于危险分层调整异基因造血干细胞移植时机、维持化疗、联合去甲基化药物或激酶抑制剂等可能有助于改善患者的整体预后。随着新的发病机制的发现,可能有更多的指标用于高危患者的识别及指导治疗策略的选择,进而提高此类患者的治疗效果,甚至达到治愈的目的。

Acute myeloid leukemia（AML）with t（8;21）is one of the common types of AML.Many studies have shown that t（8;21）AML is a group of heterogeneous diseases.Therefore,early identification of high-risk patients and further adjustment of the treatment regimen can be beneficial to improve the therapeutic effect and improve the overall prognosis of these patients.The patients could be divided into different risk groups according to co-occurring gene mutations,the initial peripheral blood leukocyte count,CD56 expression,and the level of minimal residual disease after treatment.The prognosis of high-risk patients may be improved by adjusting the timing of allogeneic hematopoietic stem cell transplantation,maintenance chemotherapy,combining hypomethylating drugs or kinase inhibitors.Furthermore,with the discovery of new pathogenesis,more indicators may be used for identification of high-risk patients,and more treatment strategies may be revealed,which will further improve the therapeutic effect of such patients and even achieve the ultimate goal of curing patients.